Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics (AXSM) to $212 from $195 and keeps an Outperform rating on the shares. The firm updated the company’s ...

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ: NASDAQ:AXSM), a biopharmaceutical company valued at $6.69 billion, announced today the successful results of their EMERGE Phase 3 trial for SYMBRAVO®, a ...

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ: NASDAQ:AXSM), a biopharmaceutical company valued at $6.69 billion, announced today the successful results of their EMERGE Phase 3 trial for SYMBRAVO ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) shares hit a new 52-week high during trading on Friday after HC Wainwright raised their price target on the stock from $190.00 to $200.00.

Shares of AXSM stock opened at $137.75 on Thursday. The company has a market cap of $6.72 billion, a P/E ratio of -23.00 and a beta of 1.05. Axsome Therapeutics has a fifty-two week low of $64.11 ...

Axsome Therapeutics' stock has risen 47% since my August recommendation, driven by FDA approvals and revenue growth, but I maintain a "sell" rating. Despite Auvelity's revenue growth, significant ...

NEW YORK (AP) — NEW YORK (AP) — Axsome Therapeutics Inc. (AXSM) on Tuesday reported a loss of $74.9 million in its fourth quarter. The New York-based company said it had a loss of $1.54 per share.

Axsome Therapeutics' Q4 revenue surged to $118.77 million, surpassing expectations with significant growth in Auvelity sales. Axsome reports progress on multiple drug applications, including ...

Biopharmaceutical firm Axsome Therapeutics (NASDAQ:AXSM) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales ...

“2024 was another defining year for Axsome, driven by strong commercial growth and a rapidly advancing late-stage pipeline, which culminated in the successful completion of our Phase 3 clinical ...